Managers / Q3 2021 · view latest →
Athyrium Capital Management, LP
CIK 0001728001 · 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NY, 10017 · 212-402-6925
Summary
Athyrium Capital Management, LP reported $158M in U.S.-listed holdings across 5 positions for Q3 2021.
The portfolio is heavily concentrated: Progenity alone accounts for 35.1% of reported value.
The book was largely unchanged from Q2 2021.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 97.1% · $153M
- Common Stock · 2.9% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CAREMAX INC | ADDED | +610.7K | 4.49M | −$7M | $43M |
| Progenity Inc. | HELD | +0 | 36.40M | −$75M | $55M |
| RAHRecro Pharma Inc. | HELD | +0 | 2.20M | −$551,000 | $5M |
| Amryt Pharma PLC | HELD | +0 | 4.52M | −$385,000 | $54M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Progenity Inc. | COM | 35.09% | $55M | 36.40M |
| 2 | Amryt Pharma PLC | Sponsored ADS | 34.53% | $54M | 4.52M |
| 3 | CAREMAX INC | COM CL A | 27.50% | $43M | 4.49M |
| 4 | RAHRecro Pharma Inc.history → | COM | 2.88% | $5M | 2.20M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $9M | 2 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $34M | 3 | Aug 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $73M | 3 | May 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $69M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $114M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $154M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $279M | 8 | May 16, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2022 | $238M | 11 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $267M | 11 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $238M | 11 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $281M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $280M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $158M | 5 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $240M | 5 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $198M | 4 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 3 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5M | 1 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $9M | 1 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $98M | 2 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $104M | 3 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.